Ocugen announces positive Phase 2/3 study results of its COVID-19 vaccine candidate COVAXIN
This study enrolled 419 US adult participants that were randomised 1:1 to receive two doses of COVAXIN or placebo, 28 days apart. Blinded safety results and preliminary unblinded immunogenicity results are available through day 56, one month following the second vaccination. The top-line data from the immunobridging and broadening study will be critical to support Ocugen
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!